Skip to main content

Advertisement

Table 1 Patients’ characteristics

From: Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy

Characteristic All pts. Initial diagnosis PSA relapse PSA persistence
Number 129 20 49 60
Age (years; median, range) 72 (47–86) 76 (53–86) 74 (50–83) 69 (47–83)
Gleason Score [pts]
 6 11 (8.5%) 3 (15%) 7 (14.3%) 1 (1.7%)
 7a 27 (20.9%) 3 (15%) 19 (38.8%) 5 (8.3%)
 7b 37 (28.7%) 6 (30%) 11 (22.4%) 20 (33.3%)
 8 18 (14%) 3 (15%) 7 (14.3%) 8 (13.3%)
 9 34 (26.4%) 5 (25%) 5 (10.2%) 24 (40.0%)
 10 2 (1.6%) 2 (3.3%)
Risk group (D’Amico) [pts]
 low 5 (3.9%) 1 (5.0%) 3 (6.1%) 1 (1.7%)
 intermediate 21 (16.3%) 2 (10.0%) 13 (26.5%) 6 (10.0%)
 high 103 (79.8%) 17 (85%) 33 (67.3%) 53 (88.3%)
PSMA PET positive [pts] 92 (71.3%) 20 (100%) 27 (55.1%) 45 (75%)
PSA PRE-PSMA PET [ng/ml] (median/mean, range) 0.86/6.04 (0.13–150.00) 12.4/27.28 (0.14–150.0) 0.49/1.00 (0.15–6.24) 0.99/3.08 (0.13–39.2)
PSA doubling time
  ≤ 10 months 81 (74.3%) 21 (42.9%) 60 (100%)
  > 10 months 28 (25.7%) 28 (57.1%)
ADT at time of PET [pts] 14 (10.9%) 2 (10%) 4 (8.2%) 8 (13.3%)
Activity of 68Ga-PSMA-HBED-CC [MBq] (mean, range) 190.43 (87–293) 197.50 (100–293) 192.07 (94–293) 186.85 (87–286)
  1. (Pts patients, PSA prostate specific antigen, ADT androgen deprivation therapy, MBq Mega-Becquerel)